Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Amgen
Biotech
Amgen halts gastric cancer trial after subpar efficacy analysis
Fortitude-102 was testing bemarituzumab, a monoclonal antibody, in combination with chemotherapy and BMS’ Opdivo in 515 patients.
Darren Incorvaia
Nov 5, 2025 4:35am
Evoq Therapeutics signs on with Sanofi in $500M partnership
Oct 16, 2025 10:25am
CatalYm catalyzes C-suite shake-up—Chutes & Ladders
Sep 19, 2025 8:30am
Amgen-Zai stomach cancer asset loses OS benefit in final analysis
Sep 3, 2025 4:33pm
Amgen looks to level up clinical trials with Veeva pact
Sep 2, 2025 3:05pm
Amgen unveils plans for $600M R&D site in California
Sep 2, 2025 11:08am
